Natural killer (NK) cells generated after haploidentical hematopoietic SCT in patients with AML are characterized by specific phenotypic features and impaired functioning that may affect transplantation outcome. We show that IFN-c produced by immature CD56
Introduction
Natural killer (NK) cells comprise approximately 10% of the lymphocytes circulating in the blood. They are characterized by their inherent ability to recognize potentially harmful cells and play a major role in innate immunity against tumorigenesis. A variety of inhibitory and activating receptors expressed on the surface of NK cells regulate their functions. [1] [2] [3] In particular, the binding of certain inhibitory receptors to their corresponding MHC class I molecules delivers a negative signal that results in the inhibition of certain NK cell functions, such as cellmediated cytotoxicity and cytokine release. 4, 5 Two major classes of HLA class I binding receptors can be expressed on NK cells: the KIR and the heterodimer formed by the C-type lectin molecules CD94 and NKG2A. The ligands for KIR are the classical class I molecules HLA-A, -B and -C, whereas the CD94/NKG2A heterodimer binds to the non-classical class I molecule HLA-E. 1, 6 Interestingly, a recent model of human NK-cell development proposes that the progression of NK cells development is marked by the acquisition of CD94/NKG2A expression by CD56 bright NK cells, before the acquisition of other NK cell markers including NKG2D and NKp46, which confer MHC class Idependent inhibition. 7 This stage precedes the last step of the NK cell development, including the progression of CD56 bright to CD56 dim NK cells that was originally reported by Lanier et al. 8 Studying patients undergoing hematopoietic SCT provides a unique in vivo opportunity to analyze NK cell maturation. NK cell receptors are expressed at late stages in NK cell development. CD56 bright NK cells typically express CD94/NKG2A at high frequency and are weakly cytotoxic, but produce a high level of cytokines. 7, 9 We reported earlier that NK cells generated following haplomismatched SCT recover very fast, within 2-3 weeks, and are characterized by specific phenotypic features including higher CD94/NKG2A expression than in NK cells from healthy donors and impaired NK lysis against primary mismatched AML blasts. 10, 11 These differences, also observed in other hematopoietic transplantation situations, correlate with clinical outcome and could be because of incomplete NK cell development, which limits the potential of these NK cells to control infection and malignancy. [12] [13] [14] The lytic function of NK cells is markedly influenced by the recognition of class I MHC molecules, a process mediated by several types of activating and inhibitory receptors expressed on the NK cells. One of the most important of these mechanisms of regulation is the recognition of the non-classical class I MHC molecule HLA-E, in complex with nonamer peptides derived from the signal sequences of certain class I MHC molecules, by heterodimers of the C-lectin-like proteins CD94 and NKG2. 5, 15 Thus, the interaction of CD94/NKG2A with HLA-E can be thought of as a strategy by which NK cells monitor expression of classical class I MHC molecules indirectly, through peptide-induced stabilization, and hence the surface expression of HLA-E. 16 Monitoring specific NK cytolytic activity makes it possible to assess the antitumor defense of AML patients. Analysis of the molecular basis of NK targeting and its relation to NK function after haplo-mismatched SCT reveals that the inhibitory capacity of CD94/NKG2A receptors against mismatched blasts is not because of their overexpression post transplantation but because of the direct link to the modulation of HLA-E expression on leukemic cells, leading us to postulate that HLA-E expression might represent a mechanism of tumor escape. Furthermore, overexpression of HLA-E is dependent on the IFN-g produced by immature NK cells generated after recovery from SCT, suggesting that these immature NK cells are indirectly responsible for their inefficiency against AML blasts. Collectively, these data show that NK cell development is transiently delayed at the CD56 bright stage and that the maturation-both phenotypic and functional-of NK cells is a prerequisite for an antitumor defense against AML blasts.
Materials and methods

Patients and samples
The PBMCs were obtained from healthy volunteers and 16 AML patients (Table 1 ) who received SCT from haplomismatched related donors after conditioning regimens described earlier. 12 Three of the 16 patients were in CR for at least 3 years after SCT. Patients and donors provided informed consent in compliance with ethics committee guidelines before samples were collected for the study. 
Cytofluorometric analysis
NK IFN-g production and degranulation
To stimulate IFN-g production, NK cells were incubated overnight with or without IL12 (10 ng/ml) and IL18 (100 ng/ml) (R&D Systems, Lille, France). Cells were then fixed and permeabilized with IntraPrep reagent (Beckman Coulter) and stained with anti-IFN-g MoAb (27726; R&D Systems), as described earlier. 17 NK cells were incubated with AML blasts at a 1:1 ratio in the presence of antiCD107a MoAb (H4A3; BD) for the degranulation assay.
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Results
Clinical outcome following SCT For the 16 high-risk malignant AML patients who received SCT from haplo-mismatched related donors after myeloablative regiments, the outcome was very poor; only three patients survived to 2 years after SCT ( Table 1 ). The leading cause of death was relapse (8/13 patients), occurring in the early post transplantation period. Analysis HLA-E upregulation on IFN-c-activated AML blasts S Nguyen et al of DNA polymorphism in the peripheral blood revealed full donor-type chimerism in all patients 1 month after transplantation (data not shown).
Involvement of CD94/NKG2A expression in NK-mediated lysis As described earlier, CD3 À CD56 þ NK cells were detectable in all of the 16 AML recipients soon after transplantation and remained at high frequencies throughout followup. 10, 12 In line with several observations, the level of CD94/ NKG2A expression remained high in all SCT patients during the 2-year period of analysis (Figure 1a) . 12 The level of CD56 bright CD94/NKG2A þ expression in SCT patients was around 3.9 ± 1.1 times higher than in donors, both at 1-and 6-months post transplant. In contrast, 2 years after SCT, donors and patients had similar levels of bright CD94/NKG2A þ (Figure 1b ). In addition, NK cytotoxicity against AML blasts was poorer in patients than in donor cells during the first 6 months. Anti-NKG2A MoAb significantly blocked this effect (Figure 1c) . At 2 years post transplantation, however, NK lysis was observed at similar levels in patients and donors, regardless of whether anti-NKG2A MoAb was present. Consistent with these results, CD107a expression on CD94/NKG2A þ NK cells during the first 6 months post-SCT was very low-less than 10%. This NK degranulation level had increased sharply by 2 years after transplantation, to around 32%, reaching the level observed on healthy NK cells (around 35%) in the presence of mismatched AML blasts (Figure 1d ).
IFN-g protects AML blast cells from lysis by CD94/ NKG2A
þ NK cells In line with earlier studies, the ability of NK cells to produce IFN-g appeared to depend on their stage of maturation. 7 As shown in Figure 2a , intracellular IFN-g production in CD94/NKG2A þ NK cells from patients was high at 6 months post-SCT. At 2 years after transplantation, IFN-g levels fell sharply to the level seen in healthy donors. It can be noted that in the absence of target cell stimulation, the level of IFN-g was close to the background (data not shown). ELISA assays confirmed these findings: during the first 6 months post-SCT, NK cells from the SCT patients, stimulated by IL2 or IL12 and IL18, produced roughly 17.6 or 9.0 times more IFN-g, respectively, than did healthy volunteers, as others have observed.
14 At 2 years post-SCT, however, the level of IFN-g production was similar to that in controls in all conditions (Figure 2b) .
To understand the significance of these findings, we assessed the overall ability of primary AML blasts treated with IFN-g to serve as targets for NK cells. As Figure 3a shows, IFN-g markedly suppressed specific lysis in healthy volunteers. This effect was concentration dependent. Cytotoxicity fell by approximately half, at 100 IU/ml IFN-g, and was nearly undetectable at 1000 IU/ml. In contrast, neither IFN-g concentration influenced the poor lysis activity mediated by patient NK cells during the first 6 months after SCT. Interestingly, NK cytotoxicity was strongly enhanced in the presence of neutralizing anti-IFNg MoAb (Figure 3b ). This effect was time dependent; indeed, in AML patients at 2 years post transplantation, IFN-g substantially suppressed specific lysis (Figure 3a) , but the IFN-g neutralizing antibody had no effect on NK lysis against AML blasts (Figure 3b ), as shown in healthy volunteers.
IFN-g-induced expression of HLA-E by AML blast cells decreases their susceptibility to NK lysis
Similar to the classical MHC class I genes, HLA-E is induced by IFN-g through the STAT1a and GATA3 response elements. 18, 19 Current concepts about its function focus essentially on its capacity to inhibit the activities of CD94/NKG2A-expressing NK cells. 20 As shown in Figure 3c , HLA-E expression increased significantly on IFN-g treatment of AML blasts. This effect was concentration dependent. These data were confirmed by western blot (data not shown). In contrast, treatment with IFN-g had no effect on HLA-E in LCL-221-AEH cells that overexpressed it. We sought definitive proof of the relation between IFN-g-mediated HLA-E induction on AML blasts and the functional activity of inhibitory CD94/NKG2A receptor on NK cells by testing the cytolytic activity of NK cells from healthy volunteers against mismatched AML blasts pretreated by IFN-g. Figure 3d shows that anti-NKG2A MoAb treatment significantly restored cell lysis, which was abrogated in the presence of IFN-g-treated target cells. Our results show that although CD94/NKG2A is expressed similarly in NK cells at all stages after transplant, its functionality depends on the cell-surface density of HLA-E on AML blasts. Along the same line, in the presence of LCL-221-AEH cells, which overexpressed HLA-E, anti-NKG2A MoAb treatment abolished NK lysis (Figure 3d ).
Discussion
As observed earlier, a serious problem in haplo-mismatched hematopoietic SCT is the increased risk of clinical relapse. 10, 11 In this cohort, only 3-16 patients were in CR. The major reason for this poor outcome was certainly because of the high-risk leukemia patients being treated on this protocol. The feature most likely to explain the absence of lysis against the recipient AML blast cells is the persistence of the expression of CD94/NKG2A by the majority of NK cells after SCT. High expression of CD94/ NKG2A by immature NK cells in murine models appears to prevent most neonatal and prenatal NK cells from attacking self-cells. As we have shown here, AML blasts also express HLA-E, and this expression inhibited their lysis by NK cells isolated ex vivo after haplo-mismatched SCT. This inhibition was mediated by HLA-E recognition by CD94/NKG2A, which plays a role in preventing both autoreactivity and the GVL effect. In line with earlier observations, the level of CD94/NKG2A expression remained high during the 2-year period of observation. 10, 12 This is in agreement with the model of NK cell development proposed by Freud and Caligiuri 7 in which functional maturity is preceded by the expression of CD94/NKG2A, which is a prerequisite for IFN-g production. During early recovery from SCT, most of these NK cells are CD56 bright they are weakly cytotoxic but produce high levels of cytokines. Impaired cytotoxic function after SCT may be because of dysregulation of receptor expression or because of incomplete NK cell development, but in either case it could limit the potential of these NK cells to control infection and malignancy. As observed earlier, CD56 bright NK cells produce the most IFN-g. IFN-g is an important regulator of the immune response to malignancy. The significance of IFNg in relation to cancer immunity has been shown in a model of IFN-g receptor knockout mice, which suggests that IFNg is one of the most important players. 21 The data presented in this study point to a potential adverse effect that IFN-g may have on NK cell-mediated recognition of AML blasts, on the basis of the decreased susceptibility of tumor cells to NK lysis, after their IFN-g treatment and on lysis restoration by NKG2A-blocking MoAb. This was because of enhanced inhibitory signaling through the CD94/ NKG2A receptors expressed on the effector cell populations, as it was abrogated by blockade of NKG2A. These results reveal that IFN-g may shift the balance of triggering and inhibitory signals. The major ligand for CD94/ NKG2A is HLA-E. It was shown earlier that HLA-E is tightly upregulated on IFN-g-induced activation through STAT1a and GATA3 response elements. 18, 19 We have shown a dose-dependent link between increased cell-surface expression of HLA-E on AML blast cells and IFN-g treatment. IFN-g has earlier been reported to protect ovarian carcinoma and melanoma cells from lysis through a CD94/NKG2A-dependent pathway. 17, 22 Similar effects are reported during virus infections. Tomasec et al. 23 showed that co-infection of fibroblasts with high amounts of recombinant adenovirus encoding HLA-E and UL40 CVM protein results in increase of HLA-E expression and protection against NK lysis through CD94/NKG2A. Similar results were obtained by co-transfection of UL40 and HLA-E in K562 cells. 24 More interestingly, Cerboni et al. 25 have extended these results by showing how IFN-g can increase the inhibitory effect of UL40, through the upregulation of HLA-E. These findings may have important biological implications and support the hypothesis that IFN-g released during an antiviral or antitumoral response may lead to enhanced inhibitory signaling to effector cells carrying the CD94/NKG2A receptors and thereby turn off their effector functions. 26 Following transplantation, the occurrence of a 'cytokine storm,' which included the production of proinflammatory cytokines such as TNF-a, IL-1 and IL-6, and its impact on transplant-related complications have been described. 27 However, the impact of IFN-g in post transplant events (GVHD, GVL and infections) is more complex. 28 In line with earlier studies, the ability of NK cells to produce IFNg depended on their stage of maturation. 7 In fact, in AML patients at 2-years post transplantation, their IFN-g level of production fell sharply and returned to that in controls. This is in relation to the kinetics of NK cell repertoire reconstitution, at 2 years after SCT, when a great proportion of NK cells were CD56 dim and fully functional; NK lysis was observed at similar levels in patients and donors, regardless of whether anti-NKG2A MoAb was present. Similarly, at this point, IFN-g substantially suppressed specific lysis but anti-IFN-g neutralizing MoAb had no effect. This means that the low level of HLA-E currently present on AML blast cells is not sufficient to induce an inhibitory signal through CD94/NKG2A. Further support for this interpretation provides for binding studies of soluble recombinant HLA-E molecules and soluble CD94/NKG2A proteins, which revealed a threshold-like behavior of interaction between HLA-E and CD94/NKG2A. 29 Taken together, these data suggest that NK cells exert quality control that is essentially based on their ability to sense the level of HLA-E expression by target cells. Several checkpoints appear to prevent the destruction of healthy cells by immature NK cells. 7, 30, 31 One of these is the overexpression of HLA-E by IFN-g-produced NK cells.
Indeed, IFN-g, similar to a physiological regulator of MHC expression, potentiated and allowed a consistent manifestation of the inhibitory effect, through an HLA-E and CD94/ NKG2A-dependent mechanism. Consequently, the immature NK cells generated after haplo-mismatched SCT were ineffective in destroying AML blasts. This suggests that HLA-E may be considered a key component of the immune escape strategy against the NK attack on AML blasts that has recently been observed after haplo-mismatched SCT. 10, 11, 32 Hopefully, new therapeutic strategies will be developed soon. Recent preliminary data suggest that adoptively transferred mature NK cells in leukemic patients are not only well tolerated and can be expanded in vivo, but could promote a graft leukemia effect. 33, 34 Larger clinical trials may determine the precise benefit of this approach.
